Information Links
Opthamology news

New class of glaucoma treatment launched
A new combination product for glaucoma marks the first...

Chloramphenicol eye drops safe for under 2s, says MHRA
The balance between the benefits and risks of chloramphenicol...

Chloramphenicol eye drop contraindication advice published
Advice on the contraindication for use of chloramphenicol...

Paediatric contraindication for chloramphenicol eye drops
Chloramphenicol eye drops should no longer be used...

Dry eye products summarised in new MIMS table
More than 80 treatment options for dry eye are summarised...

Doctors identify 50 'unnecessary' medical interventions
A list of 50 tests, treatments and procedures 'of questionable...

Two new glaucoma preparations in preservative-free multi-dose bottles
Eydelto (dorzolamide) and Eylamdo (dorzolamide/timolol)...

Warn patients to report visual disturbances during steroid treatment, GPs advised
Central serous chorioretinopathy (CSCR) is a retinal...

Idebenone launched as first treatment for mitochondrial eye disease
Patients with Leber's hereditary optic neuropathy (LHON)...

Increased reports of eye irritation with Xalatan
The risk of eye irritation in patients using Xalatan...

NICE recommends two treatments for diabetic macular oedema
New guidance from NICE approves the use of aflibercept...

Tafluprost/timolol now available as combined glaucoma treatment
Taptiqom is a fixed-dose combination of the prostaglandin...

News in brief - October 2014 (updated)
Other new launches, licence changes and updates relevant...

Simbrinza: new combination glaucoma treatment
Simbrinza (brinzolamide/brimonidine) is licensed for...

Neoral approved for treatment of sight-threatening uveitis
Neoral (ciclosporin) can now be used for severe refractory...

News in brief - January 2014
Other new launches, licence changes and updates relevant...

Latest approvals from the SMC
Positive opinions on Lyxumia (lixisenatide), Sayana...

News in brief - September 2013
Other new launches, licence changes and updates relevant...